Axiom Ventures
VC Fund
Hartford, United States
Axiom Ventures is a financial organisation which targets its investments in the high technology(communications, software, Internet infrastructure and information technology) and biotechnology sectors. They invest in companies throughout the United States.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Axiom Ventures invests in
MedicalHealth CareSoftwareBiotechnologyPharmaceutical
Stages Axiom Ventures invests in
Series CFunding RoundSeries ASeries DSeries B
Countries Axiom Ventures invests in
United StatesCanada
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Mendelson
|
|||
|
Barry Bronfin
|
|||
John Wieczorek
|
|||
Samuel McKay
|
|||
Investment Focus
Industry
- Medical 4 (21%)
- Health Care 4 (21%)
- Software 3 (16%)
- Biotechnology 3 (16%)
- Pharmaceutical 3 (16%)
Stage
- Series C 6 (32%)
- Funding Round 5 (26%)
- Series A 2 (11%)
- Series D 2 (11%)
- Series B 1 (5%)
Country
- United States 13 (68%)
- Canada 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alan Mendelson
Founder
|
Founder | Total investments: 0 | Find email | |
|
Barry Bronfin
Partner
|
Partner | Total investments: 0 | Find email | |
|
John Wieczorek
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Samuel McKay
Co-founder, General Partner
|
Co-founder, General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tangen Biosciences
|
Tangen Biosciences LLC develops medical instrument that provides rapid nucleic acid detection, with the specificity and sensitivity of polymerase chain reaction (PCR) amplification. | Series A / Jun 20, 2019 | |
Melinta Therapeutics
|
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issuesfacing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. | $25M / Series D / Jan 25, 2009 | |
MX Logic
|
MX Logic, Inc. provides managed email and Web security services in the United States and internationally. It offers Email Defense Solutions that protect against email-borne threats and help businesses to meet compliance regulations via email storage, retrieval, and surveillance.The company also provides Message Archiving for businesses tomonitor, store, and retrieve company email messages to comply with electronic security regulations; and Web Defense Service that blocks Web threats, including spyware, viruses, and phishing attacks. It serves public companies, as well as companies in healthcare, financial services, and law and insurance markets.The company was founded in 2002 and is headquartered in Englewood, Colorado. | $5.7M / Series G / Nov 04, 2008 | |
Small Bone Innovations
|
Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $36M / Series C / Jan 01, 2008 | |
|
MX Logic
|
MX Logic, Inc. provides managed email and Web security services in the United States and internationally. It offers Email Defense Solutions that protect against email-borne threats and help businesses to meet compliance regulations via email storage, retrieval, and surveillance.The company also provides Message Archiving for businesses tomonitor, store, and retrieve company email messages to comply with electronic security regulations; and Web Defense Service that blocks Web threats, including spyware, viruses, and phishing attacks. It serves public companies, as well as companies in healthcare, financial services, and law and insurance markets.The company was founded in 2002 and is headquartered in Englewood, Colorado. | $2.7M / Series G / Dec 19, 2007 | |
|
MX Logic
|
MX Logic, Inc. provides managed email and Web security services in the United States and internationally. It offers Email Defense Solutions that protect against email-borne threats and help businesses to meet compliance regulations via email storage, retrieval, and surveillance.The company also provides Message Archiving for businesses tomonitor, store, and retrieve company email messages to comply with electronic security regulations; and Web Defense Service that blocks Web threats, including spyware, viruses, and phishing attacks. It serves public companies, as well as companies in healthcare, financial services, and law and insurance markets.The company was founded in 2002 and is headquartered in Englewood, Colorado. | $4M / Series F / Nov 07, 2006 | |
|
Melinta Therapeutics
|
Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issuesfacing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus. | $50M / Series C / Jun 20, 2006 | |
Airwide Solutions
|
Airwide Solutions is a global leader in providing mobile infrastructure software to enable, enhance and ensure mobile communications for over 70 wireless operators worldwide. Airwide Solutions was founded in 2004 following the merger of Schlumberger Messaging Solutions (MSG) and Taral Networks. Airwide Solutions has a rich tradition of innovation;it sent the first commercial SMS (short message service) in 1992 and deployed the first A2P (application-to-person) MMS push gateway in 2004. Airwide Solutions has regional offices in England, Canada, India, Australia, Singapore and the United States. | $25M / Series D / Jan 25, 2006 | |
|
Small Bone Innovations
|
Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $42.2M / Series B / Dec 16, 2005 | |
BioMimetic Therapeutics
|
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions,the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse.BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee. | $11.8M / Series C / May 18, 2005 | |
| See all 19 investments → | |||
Co-Investors
Kodiak Venture Partners
4 deals together
Adams Street Partners
3 deals together
Vista Ventures
3 deals together
3i Group
2 deals together
ABS Ventures
2 deals together
Artiman Ventures
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Axiom Ventures invest in?
Axiom Ventures invests primarily in Medical, Health Care and Software startups, most often at Series C and Funding Round stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Axiom Ventures?
Public channels for Axiom Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Axiom Ventures?
The team at Axiom Ventures includes Alan Mendelson (Founder), Barry Bronfin (Partner) and John Wieczorek (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
